North America accounted for the largest share of the ablation device market in 2022. The US accounted for the largest share of the largest ablation device market in 2022, and it is likely to continue this trend during 2022–2030. As per the American Cancer Society estimates, more than 1.9 million people were diagnosed with cancer in 2021, and 608,570 people died due to the disease. Moreover, 1 in 2 men and 1 in 3 women are likely to be diagnosed with cancer in their lifetime in the US. Thus, the high prevalence of cancer among people fuels the ablation device market growth in the US.

According to the US Centers for Medicare & Medicaid Services, the national healthcare expenditure in the US increased by 2.7% in 2021, reaching US$ 4.3 trillion or US$ 12,914 per person. Also, health spending accounted for 18.3% of the national Gross Domestic Product (GDP). As per the US Department of Health & Human Services, national health spending is estimated to grow at an annual rate of 5.4% during 2019–2028, reaching US$ 6.2 trillion by 2028. A rise in healthcare expenditure can potentially lead to increased funding in research and development studies related to drugs, fueling the demand for ablation devices in academics.

Increasing Demand for Minimally Invasive Procedures Drives Ablation Device Market Growth

The noteworthy advantages of minimally invasive procedures over traditional open surgeries include smaller incisions, shorter recovery time, reduced pain, and lower complication risks. Minimally invasive treatments employ advanced technologies for the identification and management of a variety of disorders, including cancer. These techniques have been implemented to remove cancer tumors and lymph nodes without any scars. Surgeons may also use minimally invasive procedures to collect tissues for biopsy and precise staging tests, which enables them to devise precise cancer therapy programs.

According to the Department of Radiology & Biomedical Imaging of the University of California San Fransisco (UCSF), small renal tumors that haven’t spread beyond the kidneys can be treated by microwave ablation (MWA) and radiofrequency ablation (RFA) as practical alternatives to surgical resection. MWA and RFA are minimally invasive, nonsurgical procedures with a recovery time of less than 24 hours. Ablation devices play a crucial role in enabling minimally invasive surgeries by offering precise tissue destruction through various energy modalities. Thus, the burgeoning popularity of minimally invasive procedures fuels the ablation device market growth.

Ablation Device Market: Segmental Overview

The ablation device market is categorized on the basis of device, application, and end user. Based on the device, the market is segmented into radiofrequency devices, laser/light ablation, ultrasound devices, cryoablation devices, and others. Based on application, the market is divided into cancer treatment, cardiovascular disease treatment, ophthalmologic treatment, gynecological treatment, urological treatment, cosmetic surgery, and others. In terms of end user, the ablation device market is categorized into hospitals and clinics, ambulatory surgical centers, and others. The ablation device market, based on geography, is segmented into North America (US, Canada, and Mexico), Europe (Germany, France, Italy, UK, Russia, and Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Ablation Device Market: Competitive Landscape and Key Developments

Abbott Laboratories, AtriCure, Inc., Biotronik, AngioDynamics, Inc., Boston Scientific Corporation, Johnson and Johnson, Conmed Corporation, Medtronic PLC, Smith & Nephew PLC, and Olympus Corporation are a few of the major companies operating in the ablation device market. These companies adopt product innovation strategies to meet evolving customer demands, which allows them to maintain their brand name in the ablation device market.  

A few of the recent developments in the global ablation device market are mentioned below:

• In May 2023, Abbott received US Food and Drug Administration (FDA) approval for its TactiFlex Ablation Catheter (Sensor Enabled), which became the world’s first ablation catheter featuring a flexible tip and contact force technology.
• In February 2023, the NovaSure V5 global endometrial ablation (GEA) device of Hologic Inc. was approved for medical usage in Canada and Europe. This innovative version incorporates enhanced features for the treatment of a broad range of cervical and uterine anatomies.
• In November 2021, Medtronic India launched the Arctic Front Cardiac Cryoablation Catheter System for atrial fibrillation (AF) treatment in the country. The system is used to perform minimally invasive cryoballoon catheter ablation, one of the therapeutic modalities used to manage AF.
• In January 2021, Medtronic plc received FDA approval for the DiamondTemp Ablation (DTA) system, which is indicated for treating patients with recurrent, symptomatic paroxysmal AF, particularly for those who have been unresponsive to conventional drugs. The DTA is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds, which is currently available to deliver ablations.
• In December 2020, Acutus Medical launched the AcQBlate Force Sensing Ablation System in Europe. The product was launched after securing the CE Mark for the AcQBlate Force ablation catheter and the Qubic Force Sensing Module. AcQBlate Force incorporated by this ablation system is the only commercially available gold-tipped, irrigated, force-sensing radiofrequency ablation catheter on the market. The system also integrates two state-of-the-art components made available through Acutus Medical’s international alliance with BIOTRONIK—the Qubic RF and the Qiona Irrigation Pump.
• In November 2020, Abbott announced the launch of the IonicRF Generator, a device cleared by the FDA to deliver a nonsurgical, minimally invasive treatment for the management of pain in the nervous system. This RF ablation device uses heat to target specific nerves and block pain signals from reaching the brain. The device is currently approved for sale in the US and Europe.